Reversible Binding Surface

• US 20080003659A1
• Filed: 04/07/2005
• Published: 01/03/2008
• Est. Priority Date: 04/15/2004
• Status: Active Grant

• Current Assignee: Corning Incorporated
• Original Assignee: Corning Incorporated
• Inventors: Day, Anthony, Short, Rob
• Granted Patent: US 8,409,874 B2
• Time in Patent Office: Days
• US Class Current: 435/239
• CPC Class Codes: B01J 20/3242 Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
• CPC Class Codes: C07K 1/22 Affinity chromatography or related techniques based upon selective absorption processes

Abstract

The present invention relates to a method to treat a product which product comprises a surface which surface includes a plasma polymer of an organic monomer wherein immobilised on said plasma polymerized surface is at least one biological entity comprising, contacting said product with an agent that promotes, either directly or indirectly, the disassociation of said entity from said product.

Claims

1. A method for the selective disassociation of at least one biological entity from a plasma polymerized surface of an organic monomer comprising contacting said surface with at least one agent which either directly or indirectly promotes disassociation of said entity from said surface.

2. A method according to claim 1 wherein said biological entity is a carbohydrate.

3. A method according to claim 2 wherein said carbohydrate is a homopolysaccharide.

4. A method according to claim 2 wherein said carbohydrate is a heteropolysaccharide.

5. A method according to claim 4 wherein said heteropolysaccharide is a glycosaminoglycan.

6. A method according to any of claims 2-5 wherein said carbohydrate is a sulphated biomolecule.

7. A method according to claim 5 wherein said glycosaminoglycan is selected from the group consisting of:

hyaluronan;

dermatan sulfate;

chondroitin sulphate;

heparin;

heparan sulphate;

or keratan sulphate.

8. A method according to claim 1 wherein said biological entity is a polypeptide.

9. A method according to claim 1 wherein said biological entity is a nucleic acid molecule.

10. A method according to claim 9 wherein said nucleic acid molecule is selected from the group consisting of deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and peptide oligonucleotides (PNAS).

11. A method according to claim 1 wherein said biological entity is a cell or viral particle.

12. A method according to claim 1 wherein said surface comprises a plasma polymer of a volatile acid.

13. A method according to claim 12 wherein said surface comprises at least 5% of said volatile acid.

14. A method according to claim 1 wherein said surface comprises a plasma polymer of a volatile alcohol.

15. A method according to claim 1 wherein said surface comprises a plasma polymer of a volatile amine.

16. A method according to claim 1 wherein said surface comprises a mixture of volatile acid and volatile hydrocarbon.

26. A method according to claim 6 wherein said glycosaminoglycan is selected from the group consisting of:

hyaluronan;

dermatan sulfate;

chondroitin sulphate;

heparin;

heparan sulphate;

or keratan sulphate.

27. A method according to claim 10 wherein said DNA is selected from cDNA, genomic DNA, single stranded DNA and oligonucleotides.

17. A method to treat a product which product comprises a surface which surface includes a plasma polymer of an organic monomer wherein immobilised on said plasma polymerised surface is at least one first biological entity, comprising the steps of

i) contacting said product with an agent that promotes, either directly or indirectly, the disassociation of said first biological entity from said surface;

and

ii) contacting said product with a second biological entity to further provide said surface with an immobilised biological entity;

wherein said first biological entity may be of the same or of a different chemical nature from said second biological entity.

18. A method according to claim 17 wherein said first or said second biological entity is a carbohydrate.

19. A method according to claim 18 wherein said carbohydrate is a homopolysaccharide.

20. A method according to claim 18 wherein said carbohydrate is a heteropolysaccharide.

21. A method according to claim 20 wherein said heteropolysaccharide is a glycosaminoglycan.

22. A method according to claim 21 wherein said glycosaminoglycan is selected from the group consisting of hyaluronan, dermatan sulfate, chondroitin sulphate, heparin, heparan sulphate, and keratan sulphate.

23. A method according to claim 17 wherein said first or said second biological entity is a polypeptide.

24. A method according to claim 17 wherein said first or said second biological entity is a nucleic acid.

25. A method according to claim 17 wherein said first or said second biological entity is a cell or viral particle.